DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

Safety and Tolerability of Oral Proglumide for NASH

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis

Interventions: Drug: Proglumide

First Posted Date: 2019-11-05

Last Posted Date: 2022-10-13

Lead Sponsor: Georgetown University

Target Recruit Count: 18

Registration Number: NCT04152473

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, United States

Evaluating the Effects of Kombucha as a Hyperglycemic Therapeutic Agent Within Diabetic Human Subjects

Not Applicable

Completed

Conditions: Diabetes Mellitus

Interventions: Dietary Supplement: Ginger Water
Dietary Supplement: Ginger Kombucha

First Posted Date: 2019-09-27

Last Posted Date: 2020-07-30

Lead Sponsor: Georgetown University

Target Recruit Count: 12

Registration Number: NCT04107207

Locations: 🇺🇸
Georgetown University MedStar Hospital, Washington, District of Columbia, United States

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Cabozantinib

First Posted Date: 2019-09-17

Last Posted Date: 2025-02-25

Lead Sponsor: Georgetown University

Target Recruit Count: 14

Registration Number: NCT04091750

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

"Immunomodulation in GWI (Phlebotomy)"

Conditions: Gulf War Illness

Interventions: Other: Draw blood (phlebotomy, 83 ml)

First Posted Date: 2019-08-15

Last Posted Date: 2019-08-15

Lead Sponsor: Georgetown University

Target Recruit Count: 80

Registration Number: NCT04058275

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

A Mobile Text Messaging Intervention for Indoor Tanning Addiction

Not Applicable

Completed

Conditions: Indoor Tanning

Interventions: Behavioral: Mobile text messaging intervention

First Posted Date: 2019-08-13

Last Posted Date: 2022-08-04

Lead Sponsor: Georgetown University

Target Recruit Count: 265

Registration Number: NCT04055272

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

Multimodal Perioperative Pain Management: ComfortSafe Program

Conditions: Post-operative Nausea and Vomiting
Respiratory Depression
Confusion Postoperative
Post-operative Pain

First Posted Date: 2019-08-06

Last Posted Date: 2020-10-05

Lead Sponsor: Georgetown University

Target Recruit Count: 60

Registration Number: NCT04046068

Locations: 🇺🇸
Medstar Georgetown University Hospital, Washington, District of Columbia, United States

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Phase 2

Recruiting

Conditions: Advanced Biliary Tract Cancer

Interventions: Drug: Nanoliposomal Irinotecan
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2019-07-02

Last Posted Date: 2024-12-24

Lead Sponsor: Georgetown University

Target Recruit Count: 50

Registration Number: NCT04005339

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸
Washington University School of Medicine- Siteman Cancer Center, Saint Louis, Missouri, United States

and more 1 locations

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Phase 2

Recruiting

Conditions: Dementia With Lewy Bodies

Interventions: Drug: Placebo oral capsule
Drug: Nilotinib Oral Capsule

First Posted Date: 2019-06-28

Last Posted Date: 2023-05-15

Lead Sponsor: Georgetown University

Target Recruit Count: 60

Registration Number: NCT04002674

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

K0706 for Patients Diagnosed With Dementia With Lewy Bodies

Phase 2

Recruiting

Conditions: Dementia With Lewy Bodies

Interventions: Drug: Placebo
Drug: 192 mg powder of K0706
Drug: 384 mg powder of K0706

First Posted Date: 2019-06-24

Last Posted Date: 2022-10-19

Lead Sponsor: Georgetown University

Target Recruit Count: 45

Registration Number: NCT03996460

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Talazoparib
Drug: Avelumab

First Posted Date: 2019-05-28

Last Posted Date: 2025-05-21

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT03964532

Locations: 🇺🇸
University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy